NUZE · Nuzee, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q2 '26 | Q1 '26 | Q3 '25 | Q2 '25 | Q1 '24 | Q3 '24 | Q2 '24 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.21M | $15.77M | $61.6K | - | $22.9K | $366.9K | $605.8K | $648.6K | $781.2K | $1.14M |
| Cost of Revenue | $3.20M | $15.68M | $56.4K | - | $7.4K | $513.1K | $752.0K | $596.5K | $744.5K | $1.06M |
| Gross Profit | $13.7K | $87.4K | $5.1K | - | $15.5K | ($146.2K) | ($146.2K) | $52.2K | $36.6K | $75.5K |
| R&D | - | - | - | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - | - | - | - |
| Total Operating Expenses | $1.34M | $2.08M | $1.34M | $1.27M | $1.52M | $1.34M | $1.46M | $2.07M | $1.98M | $2.28M |
| D&A | - | $1.7K | - | - | $7.8K | - | - | - | - | $73.8K |
| Operating Income | ($1.32M) | ($1.99M) | ($1.11M) | ($752.7K) | ($1.50M) | ($1.48M) | ($1.61M) | ($2.02M) | ($1.95M) | ($2.20M) |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($15.42M) | ($19.44M) | ($1.07M) | ($385.6K) | ($1.54M) | ($1.44M) | ($1.65M) | ($2.03M) | ($1.97M) | ($2.18M) |
| EPS - Basic | ($0.49) | ($1.43) | ($0.03) | ($0.03) | ($0.17) | ($0.92) | ($1.28) | ($2.63) | ($2.80) | ($5.45) |
| EPS - Diluted | ($0.49) | ($1.43) | ($0.03) | ($0.03) | ($0.17) | ($0.92) | ($1.28) | ($2.63) | - | - |
Balance Sheet
| Line item | Q2 '26 | Q1 '26 | Q3 '25 | Q2 '25 | Q1 '24 | Q3 '24 | Q2 '24 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $17.0K | $45.4K | $137.3K | $2.4K | $124.7K | $464.2K | - | $982.9K | $4.70M | $6.49M |
| Accounts Receivable | $1.39M | $1.39M | $55.3K | $79.9K | $1.13M | $371.8K | $397.6K | $586.9K | $421.6K | $653.9K |
| Inventory | - | $157 | $11.89M | $12.75M | $4.61M | $4.55M | $1.21M | $998.1K | $1.23M | $1.09M |
| Accounts Payable | $1.77M | $1.79M | $429.3K | $465.2K | $1.11M | $1.29M | - | $1.59M | $210.2K | $462.7K |
| Current Assets | $3.32M | $3.41M | $17.13M | $13.02M | $5.03M | $5.72M | $1.99M | $3.38M | $6.65M | $8.61M |
| Total Assets | $53.18M | $67.42M | $74.18M | $13.10M | $5.17M | $5.90M | $3.22M | $4.44M | $7.95M | $10.05M |
| Current Liabilities | $12.09M | $10.90M | $27.65M | $2.48M | $3.64M | $5.99M | $3.53M | $2.56M | $1.78M | $1.83M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $12.09M | $10.90M | $27.65M | $2.48M | $3.64M | $5.99M | $3.79M | $2.77M | $2.01M | $2.11M |
| Stockholders' Equity | $40.27M | $55.71M | $45.74M | $10.64M | $1.53M | ($87.3K) | ($574.9K) | $1.67M | $5.94M | $7.94M |
| Retained Earnings | ($122.10M) | ($106.67M) | ($87.23M) | ($84.27M) | ($83.88M) | ($81.93M) | ($77.17M) | ($73.37M) | ($68.77M) | ($66.81M) |
Cash Flow
| Line item | Q2 '26 | Q1 '26 | Q3 '25 | Q2 '25 | Q1 '24 | Q3 '24 | Q2 '24 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | ($8.53M) | - | - | ($1.34M) | - | - | - | - | ($1.91M) |
| Investing Cash Flow | - | - | - | - | ($307.0K) | - | - | - | - | ($16.5K) |
| Financing Cash Flow | - | $8.45M | - | - | $1.19M | - | - | - | - | ($8.9K) |
| CapEx | - | - | - | - | $307.0K | - | - | - | - | $16.5K |
| Free Cash Flow | - | - | - | - | ($1.65M) | - | - | - | - | ($1.93M) |
Ratios
| Metric | Q2 '26 | Q1 '26 | Q3 '25 | Q2 '25 | Q1 '24 | Q3 '24 | Q2 '24 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 0.4% | 0.6% | 8.3% | - | 67.7% | -39.9% | -24.1% | 8.0% | 4.7% | 6.6% |
| Operating margin | -41.2% | -12.6% | -1806.1% | - | -6573.7% | -403.8% | -265.9% | -310.8% | -249.2% | -193.7% |
| EBITDA margin | - | -12.6% | - | - | -6539.7% | - | - | - | - | -187.3% |
| Net margin | -479.7% | -123.3% | -1736.3% | - | -6722.3% | -392.5% | -273.0% | -312.3% | -251.9% | -192.1% |
| Free cash flow margin | - | - | - | - | -7201.8% | - | - | - | - | -169.8% |
| FCF / Net income | - | - | - | - | 1.07 | - | - | - | - | 0.88 |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -29.0% | -28.8% | -1.4% | -2.9% | -29.7% | -24.4% | -51.4% | -45.6% | -24.7% | -21.7% |
| Return on equity | -38.3% | -34.9% | -2.3% | -3.6% | -100.6% | 1650.3% | 287.7% | -121.0% | -33.1% | -27.5% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.27 | 0.31 | 0.62 | 5.25 | 1.38 | 0.96 | 0.56 | 1.32 | 3.74 | 4.71 |
| Quick ratio | 0.27 | 0.31 | 0.19 | 0.11 | 0.12 | 0.20 | 0.22 | 0.93 | 3.05 | 4.11 |
| Cash ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.08 | - | 0.38 | 2.64 | 3.55 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.32 | 1.21 | 1.62 | 1.23 | 3.38 | -67.61 | -5.60 | 2.65 | 1.34 | 1.27 |
| Liabilities / Assets | 0.23 | 0.16 | 0.37 | 0.19 | 0.70 | 1.01 | 1.18 | 0.62 | 0.25 | 0.21 |
| Efficiency | ||||||||||
| Asset turnover | 0.06 | 0.23 | 0.00 | - | 0.00 | 0.06 | 0.19 | 0.15 | 0.10 | 0.11 |
| Inventory turnover | - | 99881.40 | 0.00 | - | 0.00 | 0.11 | 0.62 | 0.60 | 0.61 | 0.97 |
| Days sales outstanding | 158d | 32d | 328d | - | 18040d | 370d | 240d | 330d | 197d | 210d |
| Days inventory outstanding | - | 0d | 76908d | - | 228103d | 3235d | 587d | 611d | 603d | 375d |
| Days payable outstanding | 202d | 42d | 2776d | - | 54931d | 921d | - | 972d | 103d | 159d |
| Cash conversion cycle | - | -10d | 74459d | - | 191212d | 2685d | - | -31d | 697d | 426d |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | -83.2% | - | -98.0% | -43.4% | -22.5% | -16.2% | 9.2% | 11.5% |
| Revenue CAGR (3y) | 60.3% | 140.3% | -57.0% | - | -65.3% | 24.1% | 15.5% | 50.1% | 25.7% | 27.7% |
| Revenue CAGR (5y) | 52.2% | 95.9% | -20.3% | - | -42.2% | -8.9% | 10.6% | 19.0% | 14.9% | 26.1% |
| Gross profit growth (YoY) | - | - | - | - | -79.5% | - | - | - | 3633.9% | 391.4% |
| Operating income growth (YoY) | -75.9% | - | 24.9% | 53.3% | 31.8% | 26.5% | 17.2% | 23.4% | 39.1% | 22.4% |
| Net income growth (YoY) | -3900.3% | - | 25.8% | 76.7% | 29.6% | 28.9% | 16.0% | 23.1% | 39.0% | 22.1% |
| EPS growth (YoY) | -1533.3% | - | 96.7% | 97.7% | - | 65.0% | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | 14.7% | - | - | - | - | -21.9% |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 278.5% | - | - | - | -80.7% | - | - | -82.8% | -61.6% | -35.0% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-09-30.
Business segments
$10.30M totalHomology Of Medicine And Food Series$6.35M · 61.7%
Computing Power Product Series$3.80M · 36.9%
Maca Product$144.7K · 1.4%
Adjustments And Eliminations($891) · -0.0%
Product / service
$10.30M totalProduct$10.23M · 99.4%
Service$66.0K · 0.6%
Geographic
$10.30M totalCN$10.30M · 100.0%
Peer comparison
Same SIC group: Retail-Miscellaneous Retail
Comparing NuZee against the 5 most active filers in the same SIC group.